DP
PTHS

Diadema Partners’s Pelthos Therapeutics PTHS Stock Holding History

Diadema Partners’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$520K Sell
24,773
-227
-0.9% -$5.38K 0.09% 108
2025
Q4 		$775K Buy
25,000
+14,502
+138% +$418K 0.13% 101
2025
Q3 		$294K Buy
+10,498
New +$255K 0.08% 108

Other funds holding PTHS

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Diadema Partners's PTHS Position: Q1 2026 in Review

Diadema Partners reduced its Pelthos Therapeutics (PTHS) stake by 0.91% in Q1 2026, selling an estimated $5.38K and leaving 24,773 shares worth $520K. The position accounts for 0.09% of the portfolio, ranked #108.

Diadema Partners first reported a position in PTHS in Q3 2025 and has held it in 3 quarters since. The position peaked at $775K in Q4 2025. 17 funds tracked by Wall St. Rank hold PTHS as of Q1 2026.

  • Diadema Partners held 24,773 shares of Pelthos Therapeutics worth $520K as of Q1 2026.
  • Diadema Partners sold 227 Pelthos Therapeutics shares in Q1 2026, an estimated $5.38K.
  • Pelthos Therapeutics made up 0.09% of Diadema Partners's portfolio in Q1 2026, its #108 holding.
  • Diadema Partners first reported a position in Pelthos Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Diadema Partners's Pelthos Therapeutics position peaked at $775K in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.